The 8^th International Workshop on Human Leucocyte Differentiation Antigens （chaired by HZ and managed by BS） was run over a 4-year period and culminated in a conference in December 2004. Here we review the achievem...The 8^th International Workshop on Human Leucocyte Differentiation Antigens （chaired by HZ and managed by BS） was run over a 4-year period and culminated in a conference in December 2004. Here we review the achievements of the HLDA Workshops and provide links to information on CD molecules and antibodies against them, including the 93 new CDs assigned in the 8^th Workshop. We consider what remains to be achieved （including an estimate of the number of leucocyte surface molecules still to be discovered）, and how the field can best move forward.展开更多
Features of CD20^+T cells:CD20 is a membrane-spanning hosphoprotein strongly expressed on the cell surface of B lineage cells and is widely regarded as a B cell specific marker.However,CD20(Figure 1)is also expressed ...Features of CD20^+T cells:CD20 is a membrane-spanning hosphoprotein strongly expressed on the cell surface of B lineage cells and is widely regarded as a B cell specific marker.However,CD20(Figure 1)is also expressed at a low level on a small subset of CD3^+T cells which therefore are sometimes referred to as CD20dimCD3^+T cells in contrast to CD20brightCD19^+B cells which represent the majority of cells expressing CD20(Hultin et al.,1993).The amount of the CD20 antigen has been assessed to be 25 to 50 times higher on CD20^+CD19^+B cells compared to CD20^+CD3^+T cells(Hultin et al.,1993).At first description of this cell population the frequency of these CD20^+T cells has been described to represent an average of 2.4%of all peripheral blood lymphocytes(50 healthy controls)(Hultin et al.,1993).展开更多
Nowadays, resistance to rituximab has become a major issue in clinical practice. And loss of CD20 may contribute to it. Here we presented a case of loss of CD20 expression in relapsed diffuse large B cell lymphoma tre...Nowadays, resistance to rituximab has become a major issue in clinical practice. And loss of CD20 may contribute to it. Here we presented a case of loss of CD20 expression in relapsed diffuse large B cell lymphoma treated with rituximab and discuss the incidence, mechanism, influence factors, specific markers, prognosis and treatment of this disease. These results suggested that a post-relapse biopsy after rituximab treatment shguld be performed. CD79a and Pax-5 should be used as the first-line B lineage-specific markers for these patients. Though mechanisms of CD20 decrement are not fully elucidated, the down-regulation of CD20 mRNA is the most probable hypothesis. Recently various new agents are developed, but the prognosis is still poor. Further studies for new treatments are needed.展开更多
A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression o...A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.展开更多
目的探讨韦氏环伴滤泡辅助T细胞表型的外周T细胞淋巴瘤(Waldeyer’s ring peripheral T-cell lymphoma with T-follicular helper phenotype,wPTCL-TFH)临床病理学、遗传学特征及预后。方法收集1例wPTCL-TFH临床资料,对其病变组织行HE...目的探讨韦氏环伴滤泡辅助T细胞表型的外周T细胞淋巴瘤(Waldeyer’s ring peripheral T-cell lymphoma with T-follicular helper phenotype,wPTCL-TFH)临床病理学、遗传学特征及预后。方法收集1例wPTCL-TFH临床资料,对其病变组织行HE、免疫组化染色、EBER原位杂交及TCR基因重排检测,应用一代测序法检测IDH2 Exon4基因突变情况,并复习相关文献。结果患者女性,61岁,临床表现为咽痛、消瘦,无其他发热、盗汗等B症状。组织学表现为扁桃体实质内小-中等大淋巴细胞弥漫浸润。免疫表型:肿瘤细胞表达全T细胞标志物及滤泡辅助T细胞标志物:CD10、BCL6和PD-1,弥漫表达CD20,部分表达CD30(约10%);TCR基因单克隆性重排,IDH2基因未见突变。采用R-CHOP方案化疗6个周期,随访7个月,患者无瘤生存。结论wPTCL-TFH异常表达CD20者临床罕见,化疗中加入利妥昔单抗可能对CD20异常表达wPTCL-TFH有效,仍需更多的病例进一步证实。展开更多
CD19 chimeric antigen receptor(CAR)T cells have shown robust efficacy in relapsed and refractory acute lymphoblastic leukemia(R/R ALL),but compromising result in chronic lymphoblastic leukemia(CLL)and non-Hodgkin’s l...CD19 chimeric antigen receptor(CAR)T cells have shown robust efficacy in relapsed and refractory acute lymphoblastic leukemia(R/R ALL),but compromising result in chronic lymphoblastic leukemia(CLL)and non-Hodgkin’s lymphoma(NHL).CD19-relapse and the lack of CAR-T cell persistence which result in treatment failure are considerable obstacles to overcome.CAR-T targeting CD20 is an option for salvaging CD19 CAR-T failure.Previous studies have established variant structures of bispecific CAR-T which could avoid antigen-loss and immune escape.Here,we constructed tandem and loop CAR structures targeting both CD19 and CD20 antigen.Bispecific CAR-T cells could eliminate either CD19 or CD20 negative lymphoma cells,suggesting they exhibited dual antigen targeting of CD19 and CD20.By comparing the efficiency of four bispecific CAR modified T cells,it was found that loop2019 CAR was the best structure among them to eradicate lymphoma cell lines and patients’primary lymphoma or CLL cells in a very low dose in vitro and prolong the survival time dramatically in lymphoma xenograft mice model.These data highlighted the potential of loop2019 CAR-T in clinical treatment.展开更多
文摘The 8^th International Workshop on Human Leucocyte Differentiation Antigens （chaired by HZ and managed by BS） was run over a 4-year period and culminated in a conference in December 2004. Here we review the achievements of the HLDA Workshops and provide links to information on CD molecules and antibodies against them, including the 93 new CDs assigned in the 8^th Workshop. We consider what remains to be achieved （including an estimate of the number of leucocyte surface molecules still to be discovered）, and how the field can best move forward.
文摘Features of CD20^+T cells:CD20 is a membrane-spanning hosphoprotein strongly expressed on the cell surface of B lineage cells and is widely regarded as a B cell specific marker.However,CD20(Figure 1)is also expressed at a low level on a small subset of CD3^+T cells which therefore are sometimes referred to as CD20dimCD3^+T cells in contrast to CD20brightCD19^+B cells which represent the majority of cells expressing CD20(Hultin et al.,1993).The amount of the CD20 antigen has been assessed to be 25 to 50 times higher on CD20^+CD19^+B cells compared to CD20^+CD3^+T cells(Hultin et al.,1993).At first description of this cell population the frequency of these CD20^+T cells has been described to represent an average of 2.4%of all peripheral blood lymphocytes(50 healthy controls)(Hultin et al.,1993).
文摘Nowadays, resistance to rituximab has become a major issue in clinical practice. And loss of CD20 may contribute to it. Here we presented a case of loss of CD20 expression in relapsed diffuse large B cell lymphoma treated with rituximab and discuss the incidence, mechanism, influence factors, specific markers, prognosis and treatment of this disease. These results suggested that a post-relapse biopsy after rituximab treatment shguld be performed. CD79a and Pax-5 should be used as the first-line B lineage-specific markers for these patients. Though mechanisms of CD20 decrement are not fully elucidated, the down-regulation of CD20 mRNA is the most probable hypothesis. Recently various new agents are developed, but the prognosis is still poor. Further studies for new treatments are needed.
文摘A 82-year-old man presented with an enlarged multiple superficial lymph nodes. The histological diagnosis of lymph node was peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), with an aberrant expression of CD20. Generally, PTCL lacks B cell antigen such as CD19 or CD20, however, rare cases have been reported in the literature that showed PTCL patients expressing the B cell antigens. It is considered that the prognosis of CD20 positive PTCL is poor, however, standard therapy has not been established. He was treated with eight cycles of CHOP regimen, but the enlargement of a part of lymph nodes still remained. Recently, it is reported that C-C Chemokine receptor type 4 (CCR4) is known to be expressed about 50% case of PTCL and CCR4 target therapy is effective. Our case was positive for CCR4 so mogamulizumab (anti-CCR4 antibody) was administered. Consequently, dramatic response was obtained and its combination of these therapy resulted in complete remission for 24 months. This is the first case of sustained remission by administration of mogamulizumab against CCR4/CD20 double positive PTCL. This strategy may be benefit to obtain the good prognosis.
文摘目的探讨韦氏环伴滤泡辅助T细胞表型的外周T细胞淋巴瘤(Waldeyer’s ring peripheral T-cell lymphoma with T-follicular helper phenotype,wPTCL-TFH)临床病理学、遗传学特征及预后。方法收集1例wPTCL-TFH临床资料,对其病变组织行HE、免疫组化染色、EBER原位杂交及TCR基因重排检测,应用一代测序法检测IDH2 Exon4基因突变情况,并复习相关文献。结果患者女性,61岁,临床表现为咽痛、消瘦,无其他发热、盗汗等B症状。组织学表现为扁桃体实质内小-中等大淋巴细胞弥漫浸润。免疫表型:肿瘤细胞表达全T细胞标志物及滤泡辅助T细胞标志物:CD10、BCL6和PD-1,弥漫表达CD20,部分表达CD30(约10%);TCR基因单克隆性重排,IDH2基因未见突变。采用R-CHOP方案化疗6个周期,随访7个月,患者无瘤生存。结论wPTCL-TFH异常表达CD20者临床罕见,化疗中加入利妥昔单抗可能对CD20异常表达wPTCL-TFH有效,仍需更多的病例进一步证实。
基金supported by the National Key Research&Development Program of China(2019YFA0110200)the National Natural Science Foundation of China(81830005)+1 种基金the CAMS Innovation Fund for Medical Sciences(2021-I2M-1-041)the Tianjin Applied Fundamental Research Planning Key Project(20JCZDJC00120)。
文摘CD19 chimeric antigen receptor(CAR)T cells have shown robust efficacy in relapsed and refractory acute lymphoblastic leukemia(R/R ALL),but compromising result in chronic lymphoblastic leukemia(CLL)and non-Hodgkin’s lymphoma(NHL).CD19-relapse and the lack of CAR-T cell persistence which result in treatment failure are considerable obstacles to overcome.CAR-T targeting CD20 is an option for salvaging CD19 CAR-T failure.Previous studies have established variant structures of bispecific CAR-T which could avoid antigen-loss and immune escape.Here,we constructed tandem and loop CAR structures targeting both CD19 and CD20 antigen.Bispecific CAR-T cells could eliminate either CD19 or CD20 negative lymphoma cells,suggesting they exhibited dual antigen targeting of CD19 and CD20.By comparing the efficiency of four bispecific CAR modified T cells,it was found that loop2019 CAR was the best structure among them to eradicate lymphoma cell lines and patients’primary lymphoma or CLL cells in a very low dose in vitro and prolong the survival time dramatically in lymphoma xenograft mice model.These data highlighted the potential of loop2019 CAR-T in clinical treatment.
